...effective Jan. 1. Acciriato will be succeeded by Hann Pang, VP and head of commercial, China.Hope Medicine Inc. hired...

...from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc....
...shape its pipeline and team before seeking a series A+ or B round. COMPANY PROFILE Hope Medicine Inc....
...Berkeley, Calif. Targets PRL - Prolactin PRLR - Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 AbbVie Inc. Bayer AG Hope Medicine Inc. Oncolix...

...in by Lee led the company's $36 million series A round. Chinese chronic disease company Hope Medicine Inc....
...France Genmab A/S, Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Harvard University, Cambridge, Mass. Hope Medicine Inc....
...Transmembrane protein 173 Virginia Li, Assistant Editor and Mark Zipkin, Staff Writer Neuraly Inc. Stimunity S.A.S. Storm Therapeutics Ltd. Hope Medicine Inc. Tubulis...

...male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. Hope Medicine Inc....
...PRL - Prolactin; PRLR - Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 Bayer AG Prolactin (PRL) Prolactin receptor (PRLR) Endometriosis Hair loss Hope Medicine Inc....

...and CareNet Group. EdiGENE is eligible for an additional $9 million in the series B. Hope Medicine Inc....
...pyrophosphatase/phosphodiesterase 1; PRLR - Prolactin receptor BioCentury Staff INZ-701 Cullgen Inc. Inozyme Pharma Inc. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Prolactin receptor (PRLR) EdiGENE Corp. Hope Medicine Inc....